William Blair Issues Negative Estimate for DexCom Earnings

DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at William Blair decreased their Q2 2025 earnings per share (EPS) estimates for shares of DexCom in a report released on Monday, May 5th. William Blair analyst M. Andrew now anticipates that the medical device company will post earnings of $0.46 per share for the quarter, down from their previous estimate of $0.47. The consensus estimate for DexCom’s current full-year earnings is $2.03 per share. William Blair also issued estimates for DexCom’s Q3 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.66 EPS, FY2025 earnings at $2.04 EPS, Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.65 EPS, Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $2.53 EPS.

DXCM has been the topic of a number of other reports. Canaccord Genuity Group upped their price target on shares of DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Barclays upped their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an “equal weight” rating in a research note on Monday. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Cfra Research upgraded DexCom to a “hold” rating in a report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $98.11.

DexCom Stock Performance

Shares of DexCom stock opened at $81.62 on Tuesday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock’s fifty day moving average is $71.15 and its two-hundred day moving average is $76.96. DexCom has a 52 week low of $57.52 and a 52 week high of $132.26. The company has a market capitalization of $32.00 billion, a PE ratio of 57.07, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the company posted $0.32 EPS. The company’s quarterly revenue was up 12.5% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in DexCom during the 4th quarter worth about $385,367,000. Jennison Associates LLC raised its stake in shares of DexCom by 37.7% in the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock worth $718,632,000 after purchasing an additional 2,879,489 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of DexCom by 171.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock worth $218,175,000 after purchasing an additional 2,015,971 shares during the period. Congress Asset Management Co. lifted its holdings in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the period. Finally, Fisher Funds Management LTD purchased a new stake in DexCom in the fourth quarter valued at approximately $96,507,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, COO Jacob Steven Leach sold 14,076 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares in the company, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the transaction, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at $10,002,636.06. The trade was a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 in the last 90 days. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.